Acute myelogenous leukemia as a late complication of the multimodality therapy for Hodgkin's disease.
Progressive thrombocytopenia developed in a patient following the completion of total lymphoid irradiation and combination chemotherapy for Hodgkin's disease. Thorough evaluation eventually yielded a diagnosis of acute myelogenous leukemia (AML). Previous workers have suggested that the development of thrombocytopenia with a hypoplastic marrow following total lymphoid irradiation indicated recurrent Hodgkin's disease. When the combination cytopenias and hypoplastic marrow is recognized these workers have recommended early combination chemotherapy. Recent data suggest a 1300-fold increase in the risk of AML following multimodality therapy for Hodgkin's disease. We feel that a careful search for AML should be conducted in patients with deteriorating  hematologic parameters following therapy for Hodgkin's disease and that this search should include sampling bone marrow outside irradiated areas.
D000328:Adult; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology*; D007953:Leukemia, Radiation-Induced / Q000209:etiology*; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000209:etiology; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone; D003630:Daunorubicin